title: The CARI guidelines. Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes.
authors.forename: S
authors.initials: S
authors.lastname: Chadban
authors.forename: M
authors.initials: M
authors.lastname: Howell
authors.forename: S
authors.initials: S
authors.lastname: Twigg
authors.forename: M
authors.initials: M
authors.lastname: Thomas
authors.forename: G
authors.initials: G
authors.lastname: Jerums
authors.forename: A
authors.initials: A
authors.lastname: Cass
authors.forename: D
authors.initials: D
authors.lastname: Campbell
authors.forename: K
authors.initials: K
authors.lastname: Nicholls
authors.forename: A
authors.initials: A
authors.lastname: Tong
authors.forename: G
authors.initials: G
authors.lastname: Mangos
authors.forename: A
authors.initials: A
authors.lastname: Stack
authors.forename: R J
authors.initials: RJ
authors.lastname: MacIsaac
authors.forename: S
authors.initials: S
authors.lastname: Girgis
authors.forename: R
authors.initials: R
authors.lastname: Colagiuri
authors.forename: S
authors.initials: S
authors.lastname: Colagiuri
authors.forename: J
authors.initials: J
authors.lastname: Craig
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002908:Chronic Disease; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000517:prevention & control* / Q000628:therapy; D006801:Humans; D007676:Kidney Failure, Chronic / Q000517:prevention & control* / Q000628:therapy; D012923:Social Class
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors